Experienced in Malignant Peripheral Nerve Sheath Tumor
Experienced in Malignant Peripheral Nerve Sheath Tumor
1 Gustave L Levy Pl, Box 1200, 
New York, NY 

Overview

Birte Wistinghausen is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Wistinghausen is rated as an Experienced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Leukemia, and Reticulohistiocytoma.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Malignant Peripheral Nerve Sheath Tumor.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

1 Gustave L Levy Pl, Box 1200, New York, NY 10029

Additional Areas of Focus

Dr. Wistinghausen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


20 Clinical Trials

Umbrella Long-Term Follow-Up Protocol
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Neuroblastoma Biology Studies
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 19 Less Clinical Trials
Similar Doctors
Advanced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
Advanced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
120 Mineola Blvd, Suite 460, 
Mineola, NY 
 (16.7 miles away)
Languages Spoken:
English

Sucharita Bhaumik is a Pediatric Hematologist Oncology provider in Mineola, New York. Dr. Bhaumik is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Beta Thalassemia, Neurofibromatosis Type 1 (NF1), Malignant Peripheral Nerve Sheath Tumor, and Neurofibromatosis.

Experienced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
Experienced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
1275 York Ave, 
New York, NY 
 (1.9 miles away)
Languages Spoken:
English

Leonard Wexler is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Wexler is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Hepato-Pancreato-Biliary Surgery, and Orchiectomy.

Experienced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
Experienced in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
3959 Broadway, Columbia Unversity Department Pediatric, 
New York, NY 
 (3.4 miles away)
Languages Spoken:
English

Jennifer Levine is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Levine is rated as an Experienced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Malignant Peripheral Nerve Sheath Tumor, Febrile Neutropenia, and Medulloblastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wistinghausen's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile